All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
The U.S Food and Drug Administration (FDA) has agreed to a new drug application (NDA) submission which may lead to an accelerated approval of pacritinib, a Janus kinase 2 (JAK2) and interleukin-1-receptor-associated kinase 1 (IRAK1) inhibitor, for the treatment of patients with myelofibrosis (MF) with severe thrombocytopenia (platelet < 50 × 109/L).
The application will be based on the phase III PERSIST-1 and PERSIST-2 trials where pacritinib has shown clinical superiority to best available therapy when treating JAK inhibitor-naïve patients with primary MF and thrombocytopenia, and the phase II PAC203, comparing the efficacy and safety of different pacritinib dosing schedules in patients with MF, who no longer benefitted or were intolerant to JAK inhibitors. The submission is expected to be completed in early 2021. In addition, pacritinib is currently under investigation in the phase III PACIFICA trial comparing the efficacy of 200 mg pacritinib with the physician’s choice in patients with primary or secondary MF.
For more information on the management of thrombocytopenia in patients with MF read here.
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox